As the number of pharmacoeconomic studies has grown over the past five years, the information contained in these studies has not been consistently disseminated to Managed Care Organizations (MCOs). In addition to the volume of these studies, many MCOs are not aware of the standards to which such studies should be held. We believe that these studies are best reviewed and disseminated by therapeutic class (or more narrowly). We will present an example of such a review that includes (1) the purpose of the study, (2) definitions and limitations of the condition reviewed, (3) the considered included in the study, (4) a listing and thorough review of all pharmacoeconomic studies (see below) considered, (5) statistical tests relating to publication bias, (6) conclusions, including economic consequences, recommended approaches, and limitations, (7) the expected cost impact (per member per month) on MCOs if the recommendation is adopted, and (8) the sensitivity of the recommendation to the prices of the alternative treatments. The thorough review of each pharmacoeconomic study will further address issues such as the perspective, alternatives, scientific rigor, measurement variables, complications, quality of life measures, time frame, and source of funding. To provide further consistency, any assumptions made (such as discount rate or cost of treatments) will be restated consistently among the studies. We believe that these results consistently presented, will allow MCOs to make appropriate formulary and management decisions.